Abstract
In his letter, Koh1 focused on the significant heterogeneity in the blood pressure (BP) effects of statins observed in the studies included in our meta-analysis2 and correctly identified a number of reasons that explain this large variability. Also, it should be underscored that very few of the trials available had the effect on BP as a specific outcome. In addition, Koh mentions the use of secondary sources, ie, published articles instead of primary data sets, as a potential source of bias. One may agree …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
